EXEL vs. ONC: Exelixis vs. BeOne Medicines Stock Comparison
How do Exelixis (EXEL) and BeOne Medicines (ONC) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Exelixis (EXEL) and BeOne Medicines (ONC) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Exelixis (EXEL) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | EXEL | ONC |
|---|---|---|
| Name | Exelixis Inc. | BeOne Medicines Ltd. American Depositary Shares |
| Country/Region | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 16.98 billion USD | 46.49 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | April 17, 2000 | February 3, 2016 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | EXEL | ONC |
|---|---|---|
| Total Return (1Y) | 74.98% | 30.59% |
| Total Return (3Y, Annualized) | 50.33% | 30.15% |
| Total Return (5Y, Annualized) | 31.10% | 2.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | EXEL | ONC |
|---|---|---|
| Volatility (1Y, Annualized) | 34.17% | 35.90% |
| Beta (5Y) | 0.41 | 0.59 |
| Max Drawdown (5Y) | -35.41% | -68.89% |
| Avg. Volume (3M) | 2.33M | 405.29K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | EXEL | ONC |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 0.73 |
| Sortino Ratio (1Y) | 3.23 | 1.15 |
Profitability
ROE (TTM)
Both Exelixis (EXEL) at 44.32% and BeOne Medicines (ONC) at 18.40% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
44.32%
- Max
- 109.18%
- EXEL
- 44.32%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Exelixis (EXEL) at 35.45% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.45%
- EXEL
- 35.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Exelixis (EXEL) at 40.75% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.75%
- Max
- 83.12%
- EXEL
- 40.75%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | EXEL | ONC |
|---|---|---|
| ROE (TTM) | 44.32% | 18.40% |
| ROA (TTM) | 23.52% | 8.42% |
| Net Margin (TTM) | 35.45% | 13.86% |
| Operating Margin (TTM) | 40.75% | 22.15% |
| Gross Margin (TTM) | 96.26% | 89.39% |
Growth
Revenue Growth
Both Exelixis (EXEL) at 6.98% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Exelixis (EXEL) reports EPS growth of 57.95%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.
Growth Metrics
| Metric | EXEL | ONC |
|---|---|---|
| Revenue Growth (YoY) | 6.98% | 40.23% |
| Revenue Growth (3Y CAGR) | 12.93% | 55.69% |
| EPS Growth (YoY) | 57.95% | -- |
| EPS Growth (3Y CAGR) | 70.59% | -- |
Financial Strength
Current Ratio (MRQ)
Both Exelixis (EXEL) at 3.21 and BeOne Medicines (ONC) at 3.55 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.21
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- EXEL
- 3.21
- Q1
- 2.47
- Min
- 0.10
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Exelixis (EXEL) at 0.09 and BeOne Medicines (ONC) at 0.35 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.09
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- EXEL
- 0.09
- Q1
- 0.02
- Min
- 0.00
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | EXEL | ONC |
|---|---|---|
| Current Ratio (MRQ) | 3.21 | 3.55 |
| Debt / Equity (MRQ) | 0.09 | 0.35 |
| Net Debt / EBITDA | -0.71 | -2.80 |
Dividends
Dividend Yield (TTM)
Neither Exelixis (EXEL) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- EXEL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Exelixis (EXEL) nor BeOne Medicines (ONC) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- EXEL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | EXEL | ONC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Exelixis (EXEL) at 20.83 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.83
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- EXEL
- 20.83
- Q1
- 13.30
- Min
- 0.07
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Exelixis (EXEL) at 6.80 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.80
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- EXEL
- 6.80
- Q1
- 3.01
- Min
- 0.01
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both Exelixis (EXEL) at 9.28 and BeOne Medicines (ONC) at 7.98 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.28
- Max
- 13.53
- EXEL
- 9.28
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | EXEL | ONC |
|---|---|---|
| P/E Ratio (TTM) | 20.83 | 52.17 |
| P/S Ratio (TTM) | 6.80 | 7.04 |
| P/B Ratio (MRQ) | 9.28 | 7.98 |
| Free Cash Flow Yield (TTM) | 4.47% | 2.21% |